Drugs / MK-1496
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00880568 | Apr 2009 → Nov 2010 | cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1496 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00880568 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase PLK1 inhibitor” CHEMBL5314387 ↗ |
| Modality | Small molecule | — CHEMBL5314387 ↗ |
| Route | Oral | “orally” NCT00880568 ↗ |
| Target | PLK1 | “Serine/threonine-protein kinase PLK1 inhibitor” CHEMBL5314387 ↗ |